प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Arcturus: ARCT-032 फेज़ 2 अंतरिम विश्लेषण में क्लास I CF में म्यूकस में कमी दिखी
Interim Phase 2 data from six Class I CF adults treated with 10 mg ARCT-032 for 28 days showed mucus plug and volume reductions in four of six participants on AI-enhanced HRCT. Exploratory FEV1 analysis suggested directional lung-function improvement. The company plans to start a 12-week safety and preliminary efficacy study in up to 20 CF participants in the first half of 2026.
मुख्य तथ्य
स्रोत का अंश
EX-99.1 2 e664913_ex99-1.htm EX-99.2 3 e664913_ex99-2.htm Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF participants planned to begin first half of 2026 SAN DIEGO--(BUSINESS WIRE)—Oct 21, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today an